主管高峰會議 : Implementing a Biomarker Strategy for Better Decision Making
教學課程 : BioMmarker Assay Development and Validation
研討會 : Cancer Biomarkers
The Biomarker World Congress 2008是Cambridge Healthtech Institute主辦的生物標記系列中最受矚目的活動。內容涵蓋從創藥開始到診斷流程之各生物標記相關研究領域。本會議將吸引大規模、中規模之製藥企業、生技企業、診斷檢驗企業、主要大學、臨床機關、政府國家研究機關、 CRO、新興企業、器具製造企業等特定之參加者齊聚。與會者可以互相分享寶貴經驗、強化商業及學術合作交流、評估革新技術等。此外，本會議均衡提供各種內容，包含最新研究相關技術之主題、戰略之發表、專為決策者設計的集體研討等活動。
會議主題
轉譯醫學之生物標記
藥物基因體學
生物標記檢驗的開發和檢証
分子診斷用生物標記
生物標記的臨床試驗
安全性評價及臨床藥理學之生物標記
病患選擇及治療即時觀察用之生物標記
生物標記特定戰略
遺傳學、蛋白質體學、代謝體學用生物標記
特定疾病用生物標記: 癌、CNS、發炎性病患
決定go/no-go之生物標記
規制問題
會前研討會教學課程(本課程必須另行申請。)
以目的作分類之生物標記檢驗的開發和檢証
講師
John L. Allinson, FIBMS, Director, Veeda Clinical Research Ltd.; and Viswanath Devanarayan, Ph.D., Director, Statistics, Biomarker Research, Abbott Laboratories
本會議中預定發表之一部分
Biomarkers for Pharmacodynamics and Patient Stratification Scott Patterson, Ph.D., Executive Director, Medical Sciences, Amgen Inc.
Alzheimer's Disease Biomarker Discovery: From Focused Analytes to Open Discovery Adam J. Simon, Ph.D., Senior Research Fellow, Biomarkers, Integrative Systems Neuroscience, Merck Research Laboratories
Genomic Signature Biomarkers for Bile Duct Hyperplasia Jeffrey F. Waring, Ph.D., Associate Research Fellow, Group Leader, Abbott Laboratories
Efficacy and Mechanism of Action-based Biomarkers: from Assay Development to Clinical Data Raffaella Castoldi, M.S., Head of Analytical Biology, DMPK, Accelera/Nerviano Medical Sciences
Novel Biomarker Assays: from Preclinical Development to Clinical Proof of Concept Miro Venturi, Ph.D., Novartis Biologics
Biomarkers for Clinical Development in Alzheimer Disease and Multiple Sclerosis Christine Bétard, Ph.D, Senior Director, Global Strategic Drug Development Unit, Quintiles Benefit France SNC
Classification Biomarkers in Psychiatry by "Omic" Approaches Enrico Domenici, Ph.D., Director, Molecular Psychiatry, GSK Medicines Research Centre
Identification of Bcl-2 Family Members as Biomarkers of Response to ABT-263 Treatment Stephen Tahir, Ph.D., Research Investigator, Cancer, Abbott Laboratories
Strategies to Tackle Matrix Effects in Biomarker Assays Ole Lagatie, Ph.D., Scientific Advisor, Bioanalysis, Eurofins Medinet
Imaging MALDI vs. Histologic Imaging of Cancer of the Colon- A new Diagnostic Paradigm Paul H. Pevsner, M.D., Research Associate Professor of Pharmacology, New York University School of Medicine
Comparison of Different Biomarker Endpoints for Carcinogenesis of Aristolochic Acid in Rats Tao Chen, Ph.D., Research Toxicologist, Division of Genetic and Reproductive Toxicology, FDA/NCTR
Organ and Species Comparisons of Metabolic Disease Biomarkers in Mice and Humans Andreas Freidig, Ph.D., Dr., BU Biosciences, TNO, Quality of Life
